Literature DB >> 21999406

Combined perianal-intrarectal (PI) lidocaine-prilocaine (LP) cream and lidocaine-ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy.

Luigi Cormio1, Vincenzo Pagliarulo, Fabrizio Lorusso, Oscar Selvaggio, Antonia Perrone, Francesca Sanguedolce, Pantaleo Bufo, Giuseppe Carrieri.   

Abstract

UNLABELLED: What's known on the subject? and What does the study add? Study Type - Harm Reduction RCT Level of Evidence 1b The combination of perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block effectively counteracts probe and sampling related pain during transrectal prostate biopsy, but not pain due to periprostatic infiltration. The novel combination of lidocaine-prilocaine cream and lidocaine-ketorolac gel, both administered perianal-intrarectally, provides the same probe and sampling-related pain relief than combined perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block and prevents the non-negligible pain due to periprostatic infiltration, thus leading to better overall patients' compliance to the procedure.
OBJECTIVE: • To compare the efficacy and safety of combined perianal-intrarectal (PI) lidocaine-prilocaine (LP) cream and lidocaine-ketorolac (LK) gel with combined PI LP cream and periprostatic nerve block (PPNB) in relieving pain during transrectal ultrasonography guided prostate biopsy (TPB). PATIENTS AND METHODS: • In all, 200 patients were randomized to receive combined PI LP cream and LK gel (group 1) or combined PI LP cream and PPNB (group 2) before TPB. • The 0-10-point visual analogue scale (VAS) was used for assessing pain at probe insertion and movements (VAS-1), periprostatic infiltration (VAS-2) when applied, and prostate sampling (VAS-3), as well as maximal procedural pain (MPP). • Complications occurring ≤ 20 days after the TPB were recorded.
RESULTS: • The groups were comparable for patients' age, serum PSA level, prostate volume, and cancer detection rate. • All patients tolerated the procedure well. The two anaesthetic regimens provided almost equal mean VAS-1 (0.33 vs 0.37; P= 0.701) and VAS-3 (0.52 vs 0.51; P= 0.954) scores, but patients in group 2 reported significantly greater MPP scores (0.68 vs 1.53; P < 0.001) as periprostatic infiltration was the most painful part of the procedure (mean VAS-2: 1.33). • Complications rate was similar in the two groups (1% vs 2%; P= 0.38).
CONCLUSIONS: • The novel combination of PI LP cream and LK gel provided the same probe- and sampling- related pain relief as combined PI LP and PPNB; moreover, by preventing the non-negligible periprostatic infiltration pain, it provided significantly better overall patients' compliance to the procedure. • Being safe and easy to administer, this novel non-infiltrative regimen has the potential to replace infiltrative anaesthesia in relieving pain during TPB.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21999406     DOI: 10.1111/j.1464-410X.2011.10622.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  11 in total

1.  Prostate cancer detection rates in different biopsy schemes. Which cores for which patients?

Authors:  Luigi Cormio; Vincenzo Scattoni; Fabrizio Lorusso; Antonia Perrone; Giuseppe Di Fino; Oscar Selvaggio; Francesca Sanguedolce; Pantaleo Bufo; Francesco Montorsi; Giuseppe Carrieri
Journal:  World J Urol       Date:  2012-11-25       Impact factor: 4.226

2.  Effect of patient position on pain scales during transrectal ultrasound-guided prostate biopsy.

Authors:  Yeong Uk Kim; Yoon Seob Ji; Young Hwii Ko; Phil Hyun Song
Journal:  Korean J Urol       Date:  2015-06-01

3.  Morbidity and psychological impact of prostate biopsy: the future calls for a change.

Authors:  Andrea Minervini; Gianni Vittori; Giampaolo Siena; Marco Carini
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

4.  Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?

Authors:  Ugo Giovanni Falagario; Giovanni Silecchia; Salvatore Mariano Bruno; Michele Di Nauta; Mario Auciello; Francesca Sanguedolce; Paola Milillo; Luca Macarini; Oscar Selvaggio; Giuseppe Carrieri; Luigi Cormio
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

5.  Bioptic prostatic inflammation correlates with false positive rates of multiparametric magnetic resonance imaging in detecting clinically significant prostate cancer.

Authors:  Ugo Giovanni Falagario; Marco Recchia; Giovanni Silecchia; Paola Milillo; Alessia Francavilla; Salvatore Mariano Bruno; Oscar Selvaggio; Gian Maria Busetto; Francesca Sanguedolce; Luca Macarini; Giuseppe Carrieri; Luigi Cormio
Journal:  Cent European J Urol       Date:  2021-07-07

6.  PSA Density Help to Identify Patients With Elevated PSA Due to Prostate Cancer Rather Than Intraprostatic Inflammation: A Prospective Single Center Study.

Authors:  Salvatore M Bruno; Ugo G Falagario; Nicola d'Altilia; Marco Recchia; Vito Mancini; Oscar Selvaggio; Francesca Sanguedolce; Francesco Del Giudice; Martina Maggi; Matteo Ferro; Angelo Porreca; Alessandro Sciarra; Ettore De Berardinis; Carlo Bettocchi; Gian Maria Busetto; Luigi Cormio; Giuseppe Carrieri
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

7.  Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy.

Authors:  Luigi Cormio; Giuseppe Lucarelli; Oscar Selvaggio; Giuseppe Di Fino; Vito Mancini; Paolo Massenio; Francesco Troiano; Francesca Sanguedolce; Pantaleo Bufo; Giuseppe Carrieri
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

8.  Development and Internal Validation of Novel Nomograms Based on Benign Prostatic Obstruction-Related Parameters to Predict the Risk of Prostate Cancer at First Prostate Biopsy.

Authors:  Luigi Cormio; Luca Cindolo; Francesco Troiano; Michele Marchioni; Giuseppe Di Fino; Vito Mancini; Ugo Falagario; Oscar Selvaggio; Francesca Sanguedolce; Francesca Fortunato; Luigi Schips; Giuseppe Carrieri
Journal:  Front Oncol       Date:  2018-10-16       Impact factor: 6.244

9.  Modulation of complement activation by pentraxin-3 in prostate cancer.

Authors:  Giovanni Stallone; Giuseppe Stefano Netti; Luigi Cormio; Giuseppe Castellano; Barbara Infante; Paola Pontrelli; Chiara Divella; Oscar Selvaggio; Federica Spadaccino; Elena Ranieri; Francesca Sanguedolce; Antonio Pennella; Loreto Gesualdo; Giuseppe Carrieri; Giuseppe Grandaliano
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

10.  Prospective Validation of Pentraxin-3 as a Novel Serum Biomarker to Predict the Risk of Prostate Cancer in Patients Scheduled for Prostate Biopsy.

Authors:  Ugo Giovanni Falagario; Gian Maria Busetto; Giuseppe Stefano Netti; Francesca Sanguedolce; Oscar Selvaggio; Barbara Infante; Elena Ranieri; Giovanni Stallone; Giuseppe Carrieri; Luigi Cormio
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.